Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016 (2016), Article ID 6423297, 8 pages
http://dx.doi.org/10.1155/2016/6423297
Research Article

Predictors of Survival in Esophageal Squamous Cell Carcinoma with Pathologic Major Response after Neoadjuvant Chemoradiation Therapy and Surgery: The Impact of Chemotherapy Protocols

1Department of Surgery, Show Chwan Memorial Hospital, Changhua City, Taiwan
2Division of Thoracic Surgery, Department of Surgery, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan
3Department of Pathology, Show Chwan Memorial Hospital, Changhua, Taiwan
4School of Medicine, College of Medicine, Fu-Jen Catholic University, New Taipei City, Taiwan
5National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan
6Research Assistant Center, Show Chwan Memorial Hospital, Changhua, Taiwan
7Institute of Molecular and Genomic Medicine, National Health Research Institutes, Miaoli, Taiwan

Received 31 May 2016; Accepted 23 August 2016

Academic Editor: Steven N. Hochwald

Copyright © 2016 Chia-Ying Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Ishihara, S. Yamamoto, H. Iishi et al., “Factors predictive of tumor recurrence and survival after initial complete response of esophageal squamous cell carcinoma to definitive chemoradiotherapy,” International Journal of Radiation Oncology Biology Physics, vol. 76, no. 1, pp. 123–129, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. R. A. Meguid, C. M. Hooker, J. T. Taylor et al., “Recurrence after neoadjuvant chemoradiation and surgery for esophageal cancer: does the pattern of recurrence differ for patients with complete response and those with partial or no response?” The Journal of Thoracic and Cardiovascular Surgery, vol. 138, no. 6, pp. 1309–1317, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. F.-M. Hsu, C.-C. Lin, J.-M. Lee et al., “Improved local control by surgery and paclitaxel-based chemoradiation for esophageal squamous cell carcinoma: results of a retrospective non-randomized study,” Journal of Surgical Oncology, vol. 98, no. 1, pp. 34–41, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. K. S. Roof, J. Coen, T. J. Lynch et al., “Concurrent cisplatin, 5-FU, paclitaxel, and radiation therapy in patients with locally advanced esophageal cancer,” International Journal of Radiation Oncology Biology Physics, vol. 65, no. 4, pp. 1120–1128, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. J. M. Donahue, F. C. Nichols, Z. Li et al., “Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival,” The Annals of Thoracic Surgery, vol. 87, no. 2, pp. 392–399, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Lv, X.-F. Cao, B. Zhu, L. Ji, L. Tao, and D.-D. Wang, “Long-term efficacy of perioperative chemoradiotherapy on esophageal squamous cell carcinoma,” World Journal of Gastroenterology, vol. 16, no. 13, pp. 1649–1654, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. S. G. Swisher, W. Hofstetter, R. Komaki et al., “Improved long-term outcome with chemoradiotherapy strategies in esophageal cancer,” Annals of Thoracic Surgery, vol. 90, no. 3, pp. 892–898, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. P. R. Rohatgi, S. G. Swisher, A. M. Correa et al., “Histologic subtypes as determinants of outcome in esophageal carcinoma patients with pathologic complete response after preoperative chemoradiotherapy,” Cancer, vol. 106, no. 3, pp. 552–558, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. Y.-K. Chao, S.-C. Chan, Y.-H. Liu et al., “Pretreatment T3-4 stage is an adverse prognostic factor in patients with esophageal squamous cell carcinoma who achieve pathological complete response following preoperative chemoradiotherapy,” Annals of Surgery, vol. 249, no. 3, pp. 392–396, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. C.-H. Hsu, K.-H. Yeh, L. T. Lui et al., “Concurrent chemoradiotherapy for locally advanced esophageal cancer—a pilot study by using daily low-dose cisplatin and continuous infusion of 5-fluorouracil,” Anticancer Research, vol. 19, no. 5, pp. 4463–4467, 1999. View at Google Scholar · View at Scopus
  11. C.-C. Lin, C.-H. Hsu, J. C. Cheng et al., “Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer,” Annals of Oncology, vol. 18, no. 1, pp. 93–98, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. P. H. Konits, J. Aisner, J. C. Sutherland, and P. H. Wiernik, “Possible pulmonary toxicity secondary to vinblastine,” Cancer, vol. 50, no. 12, pp. 2771–2774, 1982. View at Publisher · View at Google Scholar · View at Scopus
  13. T. Lehnert, “Multimodal therapy for squamous carcinoma of the oesophagus,” British Journal of Surgery, vol. 86, no. 6, pp. 727–739, 1999. View at Publisher · View at Google Scholar · View at Scopus
  14. E. P. Alexander, T. Lipman, J. Harmon, and R. Wadleigh, “Aggressive multimodality therapy for stage III esophageal cancer: a phase I/II study,” The Annals of Thoracic Surgery, vol. 69, no. 2, pp. 363–368, 2000. View at Publisher · View at Google Scholar · View at Scopus
  15. Z. T. Hammoud, K. A. Kesler, M. K. Ferguson et al., “Survival outcomes of resected patients who demonstrate a pathologic complete response after neoadjuvant chemoradiation therapy for locally advanced esophageal cancer,” Diseases of the Esophagus, vol. 19, no. 2, pp. 69–72, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. S. G. Swisher, W. Hofstetter, T. T. Wu et al., “Proposed revision of the esophageal cancer staging system to accommodate pathologic response (PP) following preoperative chemoradiation (CRT),” Annals of Surgery, vol. 241, no. 5, pp. 810–820, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. A.-M. Mandard, F. Dalibard, J.-C. Mandard et al., “pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations,” Cancer, vol. 73, no. 11, pp. 2680–2686, 1994. View at Publisher · View at Google Scholar · View at Scopus
  18. L. Kleinberg, J. P. S. Knisely, R. Heitmiller et al., “Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancer,” International Journal of Radiation Oncology Biology Physics, vol. 56, no. 2, pp. 328–334, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. J. V. Reynolds, C. Muldoon, D. Hollywood et al., “Long-term outcomes following neoadjuvant chemoradiotherapy for esophageal cancer,” Annals of Surgery, vol. 245, no. 5, pp. 707–716, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. S. G. Swisher, J. A. Ajani, R. Komaki et al., “Long-term outcome of phase II trial evaluating chemotherapy, chemoradiotherapy, and surgery for locoregionally advanced esophageal cancer,” International Journal of Radiation Oncology Biology Physics, vol. 57, no. 1, pp. 120–127, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. P. M. Schneider, S. E. Baldus, R. Metzger et al., “Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification,” Annals of Surgery, vol. 242, no. 5, pp. 684–692, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. S. G. Urba, M. B. Orringer, A. Turrisi, M. Iannettoni, A. Forastiere, and M. Strawderman, “Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma,” Journal of Clinical Oncology, vol. 19, no. 2, pp. 305–313, 2001. View at Google Scholar · View at Scopus
  23. C. D. Wright, J. C. Wain, T. J. Lynch et al., “Induction therapy for esophageal cancer with paclitaxel and hyperfractionated radiotherapy: a phase I and II study,” The Journal of Thoracic and Cardiovascular Surgery, vol. 114, no. 5, pp. 811–816, 1997. View at Publisher · View at Google Scholar · View at Scopus
  24. E. K. Rowinsky and R. C. Donehower, “Paclitaxel (taxol),” The New England Journal of Medicine, vol. 332, no. 15, pp. 1004–1014, 1995. View at Publisher · View at Google Scholar · View at Scopus
  25. A. D. Colevas and M. R. Posner, “Docetaxel in head and neck cancer: a review,” American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 21, no. 5, pp. 482–486, 1998. View at Publisher · View at Google Scholar · View at Scopus
  26. D. J. Adelstein, T. W. Rice, L. A. Rybicki et al., “Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy,” Journal of Clinical Oncology, vol. 18, no. 10, pp. 2032–2039, 2000. View at Google Scholar · View at Scopus
  27. M. Zemanova, L. Petruzelka, A. Pazdro et al., “Prospective non-randomized study of preoperative concurrent platinum plus 5-fluorouracil-based chemoradiotherapy with or without paclitaxel in esophageal cancer patients: long-term follow-up,” Diseases of the Esophagus, vol. 23, no. 2, pp. 160–167, 2010. View at Publisher · View at Google Scholar · View at Scopus